Differential CYPlAl inducibility, reflecting variations in aromatic hydrocarbon receptor (AHR) affinity among inbred mouse strains, is an important determinant of environmental toxicity. We took advantage of the Air polymorphism in C57BL16 and DBA/2 mice to develop an oligonudeotide-hybridization screening approach for the rapid identification of DNA sequence differences between Air alleles. Oligonudeotides containing single-base changes at polymorphic sites were immobilized on a solid support and hybridized with C57BL/6 or DBA/2 AHR cDNA radiolabeled probes. The observed hybridization patterns demonstrate that this approach can be used to detect nudeotide differences in the Air coding region with very high accuracy. In parallel experiments, we used a yeast two-hybrid system to assess phenotypic differences in AHR function. AHR activation, as measured by 13-galactosidase reporter activity in Saceharomyces cerevisiae strain SFY526, was determined following treatment with varying doses of the AHR ligand P-naphthoflavone (BNF (9) . Ahr nucleotide differences, and corresponding AHR amino-acid changes between the C57BL/6 (B6) and DBA/2 (D2) mouse strains that carry the AhA'-1 and Ahkd alleles, respectively, have been studied extensively (9-15). An A375V change has been reported to confer most of the observed phenotypic differences between B6 and D2 (15). With hepatic cytosol from B6 and D2 mice, ligand-affinity differences were found to range between 4-and 10-fold for the B6 and D2 AHRs (1618, whereas ligand-affinity differences range between 2-and 6-fold for the B6 and D2 AHRs when cDNA-expressed AHRs are studied (9, 15 (15, 22, 
One of the most challenging questions facing environmental health research today is the identification of genotype changes associated with phenotypes of increased resistance or susceptib ity to toxic environmental agents. Environmental pollutants generate varying degrees of response in an exposed population, often due to polymorphisms in the genes controlling the molecular mechanisms of the toxic response. For example, a clear genetic component exists in the susceptibility of mouse strains to many halogenated aromatic hydrocarbons (HAHs) and nonhalogenated polycyclic aromatic hydrocarbons (PAHs), such as 2,3,7,8-tetrachlorodibenzop-dioxin (dioxin) and benzo(a)pyrene (BaP), respectively. These two environmental compounds exhibit a high degree of toxicity. BaP is a potent carcinogen in animals and a suspected carcinogen in humans (1) . Dioxin is associated with a variety of systemic effects, including immunosuppression, cleft palate, and tumor promotion in animals, and chloracne, immunosuppression, and possibly cancer and heart disease in humans (2, 3) . There is no instance known so far in which dioxin or BaP toxicity or carcinogenesis in laboratory animals is not mediated by the aromatic hydrocarbon receptor (AHR), a transcriptional regulator of xenobiotic-metabolizing enzymes encoded by the mammalian AHR gene (4, 5) .
A mouse Ahr polymorphism is known to be responsible for the variation in susceptibility to PAHs and HAHs (6) (7) (8) . Four distinct mouse Ahr alleles have now been characterized, each encoding receptor proteins with differing ligand affinities (9) .
The AhA'-1, Ahrb-2, and Ahrb-3 alleles code for AHRs with higher affinity than the AHR encoded by the Ahrt allele (). The AhrbJ1 allele occurs in C57, C58, and MA/My inbred strains; the Ahtb-2 allele is carried by the C3H, BALB/cBy, and A inbred strains; the Ahr'-3 allele exists in Mus caroli, Mus spretus, and MOLF/Ei; and the AhAd allele occurs in AKR, DBA/2, and 129 strains (9) . Ahr nucleotide differences, and corresponding AHR amino-acid changes between the C57BL/6 (B6) and DBA/2 (D2) mouse strains that carry the AhA'-1 and Ahkd alleles, respectively, have been studied extensively (9) (10) (11) (12) (13) (14) (15) ). An A375V change has been reported to confer most of the observed phenotypic differences between B6 and D2 (15) . With hepatic cytosol from B6 and D2 mice, ligand-affinity differences were found to range between 4-and 10-fold for the B6 and D2 AHRs (1618, whereas ligand-affinity differences range between 2-and 6-fold for the B6 and D2 AHRs when cDNA-expressed AHRs are studied (9, 15) .
These in vitro ligand-binding assays appear not to accurately reflect the in vivo variability in this polymorphism, however, because the B6-D2 differences in hepatic aryl hydrocarbon hydroxylase (CYPlA1) inducibility in the intact mouse are much larger-in the order of 15-to 30-fold (6-8,15P.
Many of the toxic effects ofAHR ligands observed in mice also occur in exposed human populations, in which a large amount of interindividual variability is seen; however, a DNA-based explanation of the human AHR polymorphism is still to be determined.
CYPlAl inducibiity varies by more than 30- fold in humans (20) (21) (22) (23) , and Scatchard plot analyses of 106 human placental samples have shown a >35-fold difference in AHR affinity between the highest and lowest phenotype (24, 25) , yet there has not been any direct correlation established between the degree of CYPlA1 inducibility and the variation in AHR affinity in humans nucleotide or amino acid change in the human AHR has been unequivocally associated with ligand variability. Substitution of alanine for valine at position 381 (equivalent to position 375 in the mouse) was shown to increase ligand affinity several-fold in an in vitro cDNA-expression binding assay (15) ; however, the human AHR protein from the HepG2 and A431 cell lines, as well as from at least eight individuals, contains valine at position 381 in all cases (15,22,26- (Fig. 4) . erature used, Cultures were treated with varying concenfor the correct trations of dioxin, BNF, or BaP ranging from 10-10 to 10-6 M and assayed for 0-M 0 f galactosidase activity. The AHR was activated by all three ligands in a dose-dependent manner. At 10-6 M dioxin treatment resulted in a sixfold increase of I-galactosidase activity, whereas BNF, and BaP~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~. (Fig. 5A ).
To identify amino acid changes responsible for this difference in induction levels, dose-response experiments were conducted with the chimeric AHR constructs (illustrated in Fig. 1 ). We found a clear bimodality in dose-response curves of the different chimeric AHR proteins (Fig. 5B) . Regardless of other changes, all chimeras carrying alanine (Ala)-375 responded in a fashion similar to that of the B6 receptor, whereas chimeras containing valine (Val)-375 responded like the D2 receptor. In addition, plateau values at the higher doses were 1.5-to 2-fold higher for the B6-like chimeras (data not shown).
Dose-response data were fitted to a four-parameter function to estimate the dose capable of generating the half-maximal activation of the f-galactosidase reporter gene (EC50). differences reported in in vitro ligand-binding studies (9, 15) . In addition, using chimeric AHRs, we were able to verify in this biological system the importance of the A375V change in generating the low-affinity phenotype.
The yeast two-hybrid system thus appears to represent more faithfully the biological difference in CYPlAl inducibility phenotype than in vitro ligand-binding assays. In vitro, the low-affinity forms of the AHR require stabilization by molybdate eight B6-D2 chimeric AHRs. These experiments were repeated three times with comparable results; data from one representative experiment are shown. Curve fits were completed, as described above, using the data points shown. (17) , whereas in the yeast system this artificial stabilization of the AHR is not required, perhaps providing a more accurate physiological model of AHR function. In addition, different AHR phenotypes might reflect aspects ofAHR activation other than ligand binding, such as translocation to the nucleus or dimerization with ARNT (5) that are not evaluated in the in vitro ligandbinding assays.
The existence of a human AHR polymorphism to explain the observed variability in CYPlAI inducibility (20) (21) (22) and AHR affinity (2426) has been hypothesized for many years; however, conclusive evidence to demonstrate this putative polymorphism is lacking (23, 37, 38) . Among the B6, D2, C3H, and Mus spretus mouse lines, there are 12 AHR amino acid differences (9) (10) (11) (12) (13) (14) (15) . While most amino acid changes were shown to contribute greater than twofold to receptor affinity, the opal mutation contributes two-to threefold, and the A375V change contributes four-to sixfold to the differences in AHR affinity (9, 15) . It is therefore very likely that the human AHR polymorphism will be made up of at least a dozen, and probably many more, amino acid differences reflecting the variability in ligand affinity.
In this report, we have shown that a yeast-two hybrid assay can readily determine phenotypic differences observed between the B6 and D2 mouse AHR proteins, which leads us to propose that this system might be applicable to the analysis of large numbers of anticipated differences in human AHR proteins. The experiments reported herein only assessed ligand-binding and dimerization properties, and it is possible that functional polymorphisms in a human population may include other steps of the AHR signaling pathway (5 
